Built from the ground up, the ForagR  Medicines RNA-centric, in-cell framework harnesses chemical genomics to stop diseases at their source

The ForagR platform solves the challenges of selectivity, progressability, and function that have bedeviled small-molecule RNA-targeted medicines.

 

Screening, hit-to-lead, and lead optimization are performed in cells to derisk targets, identify assets, and achieve functional modulation efficiently.